XSOLLA
19.8.2024 04:01:29 CEST | Business Wire | Press release
Xsolla, a global video game commerce company, will present a series of sessions at the Devcom Developer Conference 2024 and attend Gamescom 2024, the world’s largest computer and video games event, from August 19th to August 23rd in Cologne, Germany. Xsolla is hosting six informative speaking sessions at Devcom, including two on Best Practices for Web Shop development and a Partner Spotlight.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240818573649/en/
(Graphic: Xsolla)
“This is a pivotal year in mobile game development and for building games in Europe and globally,” described Xsolla’s Chief Marketing and Growth Officer, Berkley Egenes. “These sessions will cover various topics, including engagement best practices, rules of success for creating a web shop, the gaming industry's future, approaches to community engagement, the state of the backend technology, and how to avoid five significant pitfalls.”
Xsolla will exhibit at Gamescom from Hall 2.2, Booth #A-030-B-037. Attendees can meet with Xsolla experts and participate in demonstrations of the latest solutions and offerings designed to provide opportunities for cross-play and payment for players and developers in 2024.
“It’s an incredible opportunity to connect with the vibrant game development community, share our insights, and host speaking sessions that we hope will inspire and inform,” said Egenes. “Being a part of these events is always an exciting experience, and we can’t wait to engage with fellow developers and industry professionals.”
Xsolla Speaker Sessions Schedule:
When: Monday, August 19th, 2024, 1:00 PM - 1:30 PM
Location: Xsolla Stage #5, 1st floor, Confex Center, Devcom
Topic: Engagement best practices from leading EMEA mobile game developers
Learn how Xsolla’s solutions, designed for mobile game developers, can instantly boost revenue and player engagement beyond app stores. In this session, Josephine Friday, Sales Director, US, and Berkley Egenes, Chief Marketing and Growth Officer at Xsolla, along with Joan Lluis, Producer at Tilting Point, will share techniques and explore strategies to elevate your mobile monetization efforts. Since 2020, Xsolla has led global mobile game monetization by developing solutions, including Web Shop, SDK, Instant Web Shop, and industry-first best practices guides. Don’t miss this chance to learn from the industry's experts.
When: Monday, August 19th, 2024, 1:30 PM - 2:00 PM
Location: Xsolla Stage #5, 1st floor, Confex Center, Devcom
Topic: Leveling up: The future of gaming
Join industry experts Nick Grant, Interim CEO of 80 Level, Kasper Weber, Founder & CEO of Beyond Creative, Alexander Fernandez, CEO of Streamline Media Group, and Bridget Stacy, VP of Marketing at Xsolla, for a visionary discussion on the future of the gaming industry over the next 5 years. This talk leverages proprietary and public data, insights from partners, and Xsolla’s extensive network of gaming professionals. We will delve into anticipated advancements, innovative trends, and transformative shifts. Key topics include performance projections, comparisons to other emerging industries, and detailed forecasts on how gaming will evolve and impact the global market. Don't miss this opportunity to gain valuable insights and prepare for the dynamic changes ahead in the gaming world.
When: Monday, August 19th, 2024, 2:00 PM - 2:30 PM
Location: Xsolla Stage #5, 1st floor, Confex Center, Devcom
Topic: How to fail your studio in 5 easy steps
This session, led by Manny Hachey, Accelerator Program Director at Xsolla, is aimed at new founders and teams looking to create their first startup. Relevant to any product, platform, or target audience, this talk will help you avoid five major business pitfalls. Manny Hachey shares hard-earned, painful lessons with you now to help ensure you don't make the same mistakes in the future.
When: Tuesday, August 20th, 2024, 11:30 AM - 12:00 PM
Location: Xsolla Stage #5, 1st floor, Confex Center, Devcom
Topic: Community first: publisher and indie approaches to community engagement
The biggest challenge developers face today is discoverability. Developers can no longer rely solely on publishers for community-building efforts. In this fireside chat, Andrei Podoprigora, Co-Founder & CEO of Forklift Interactive, Nathan Sölbrandt, Business Development Director - EMEA at Xsolla, and Jan Halwe, Business Development Manager at ByteRockers' Games, will explore various aspects of community building in 2024 — from iterative feedback during development to ongoing post-launch engagement. This presentation includes diverse perspectives on effectively growing and connecting with a community in the modern digital landscape.
When: Tuesday, August 20th, 2024, 12:00 PM - 12:30 PM
Location: Xsolla Stage #5, 1st floor, Confex Center, Devcom
Topic: 5 rules of success for creating a web shop for your mobile game
Web monetization for mobile games via web shops remains a top-of-mind conversation in the video games industry. With nearly 400 web shops completed, Artem Liubutov, Xsolla's Director of Products (Monetization), unveils 5 rules of success to help you get the most out of your web shop. He will present the best ways to convey additional value, reduce friction, set up LiveOps, and lead your web shop to success.
When: Tuesday, August 20th, 2024, 12:30 PM - 1:00 PM
Location: Xsolla Stage #5, 1st floor, Confex Center, Devcom
Topic: Gaming backend: To build or to buy
As consumer appetite for online and multiplayer gaming continues to rise, developers across the industry are questioning whether to build or buy a gaming backend for their next project. Join Matthew Morris, Chief Commercial Officer at Code Wizards, as he leads a panel of experts, including Jean-Philippe Steinmetz, Head of Xsolla Backend, Alexander Bergendahl, CEO of LootLocker, and Tim Morten, Founder & CEO of Frost Giant Studios, to explore the state of backend technology and address this crucial question.
Attendees can visit Xsolla at Hall 2.2, Booth #A-030-B-037, where live demonstrations of Xsolla’s Payments, Web Shop, Mobile SDK and Backend will be held throughout the event. Xsolla’s team of experts will be available to answer questions, provide insights, and discuss how these tools can be tailored to meet the unique needs of each developer and publisher.
For more information, connect and book meetings with Xsolla at the Devcom Developer Conference and Gamescom 2024, visit xsolla.events/devcom24
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240818573649/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom